Article

Ocular rosacea in childhood.

University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, USA.
American Journal of Ophthalmology (Impact Factor: 4.02). 02/2004; 137(1):138-44. DOI: 10.1016/S0002-9394(03)00890-0
Source: PubMed

ABSTRACT To describe the clinical characteristics and treatment response of ocular rosacea in the pediatric population.
Retrospective case series.
The clinic charts of consecutive pediatric cases of ocular rosacea were evaluated over a 34-month period. Minimal diagnostic inclusion criteria were the presence of posterior eyelid inflammation including meibomian gland inspissation and lid margin telangiectasis, in conjunction with conjunctival injection or episcleritis.
Six patients ranged from 3 to 12 years of age at presentation. All shared a long history of ocular irritation and photophobia. Five patients (83%) were female and had bilateral involvement. Eyelid telangiectases and meibomian gland disease were present in all cases. Three patients (50%) had sterile corneal ulcers. Only two patients (33%) had cutaneous involvement at the time of diagnosis. All patients experienced significant improvement with a combination of oral antibiotics (doxycycline or erythromycin), with or without topical antibiotics (erythromycin or bacitracin) or topical steroids (fluorometholone).
Ocular rosacea in children may be misdiagnosed as viral or bacterial infections. Unlike in adults, associated cutaneous changes are uncommon. Most disease is bilateral, although involvement may be asymmetric. Response to conventional treatment is excellent, although long-term treatment may be necessary to prevent relapses.

1 Bookmark
 · 
189 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Rosazea ist eine häufige, chronische Dermatose, die hauptsächlich das Gesicht befällt. Aufgrund der beeinträchtigten äußeren Erscheinung kann sie für den Patienten sehr belastend sein und zu psychosozialen Auffälligkeiten führen. Die Rosazea tritt im Erwachsenenalter auf, am häufigsten bei 40- bis 50-Jährigen. Der Verlauf variiert individuell, ein Abklingen der Erkrankung ist in jedem Stadium möglich. Im Allgemeinen werden 3 Hauptstadien unterschieden: die Rosacea erythematosa-teleangiectatica (Stadium I), die Rosacea papulopustulosa (Stadium II) und die glandulär hyperplastische Rosazea (Stadium III). Neben diesen 3 Hauptformen gibt es zahlreiche Sondertypen, die häufig mit differenzialdiagnostischen Schwierigkeiten einhergehen und einer spezifischen therapeutischen Strategie bedürfen. Hierzu gehören die Rosacea conglobata, die Rosacea fulminans, die granulomatöse Rosazea, das persistierende Ödem (Morbus Morbihan), die gramnegative Rosazea und die Steroidrosazea. In jüngerer Zeit wurden vermehrt Rosazeafälle beobachtet, die durch Inhibitoren epidermaler Wachstumsfaktoren (Cetuximab, Geftinib) im Rahmen der Chemotherapie verschiedener maligner Erkrankungen hervorgerufen wurden. Diese Nebenwirkungen wurden als akneiforme Eruptionen beschrieben, zumindest bei einem Teil der Patienten ähnelt das Erkrankungsbild aber der Rosazea. Daher kann diese Form als eine Untergruppe der medikamenteninduzierten Rosazea klassifiziert werden.
    Der Hautarzt 01/2013; 64(7). · 0.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective-To assess tear and plasma concentrations of doxycycline following oral administration to northern elephant seals (Mirounga angustirostris). Design-Pharmacokinetic study. Animals-18 juvenile northern elephant seals without signs of ocular disease. Procedures-Study seals were receiving no medications other than a multivitamin and were free from signs of ocular disease as assessed by an ophthalmic examination. Doxycycline (10 or 20 mg/kg [4.5 or 9.1 mg/lb]) was administered orally every 24 hours for 4 days. Tear and plasma samples were collected at fixed time points, and doxycycline concentration was assessed by means of liquid chromatography-tandem mass spectrometry. Concentration-time data were calculated via noncompartmental analysis. Results-Following administration of doxycycline (10 mg/kg/d, PO), maximum plasma doxycycline concentration was 2.2 μg/mL at 6.1 hours on day 1 and was 1.5 μg/mL at 4.0 hours on day 4. Administration of doxycycline (20 mg/kg/d, PO) produced a maximum plasma doxycycline concentration of 2.4 μg/mL at 2.3 hours on day 1 and 1.9 μg/mL at 5.8 hours on day 4. Doxycycline elimination half-life on day 4 in animals receiving doxycycline at a dosage of 10 or 20 mg/kg/d was 6.7 or 5.6 hours, respectively. Mean plasma-to-tear doxycycline concentration ratios over all days were not significantly different between the low-dose (9.85) and high-dose (9.83) groups. For both groups, doxycycline was detectable in tears for at least 6 days following cessation of dosing. Conclusions and Clinical Relevance-Oral administration of doxycycline at the doses tested in the present study resulted in concentrations in the plasma and tears of northern elephant seals likely to be clinically effective for treatment of selected cases of systemic infectious disease, bacterial ulcerative keratitis, and ocular surface inflammation. This route of administration should be considered for treatment of corneal disease in northern elephant seals and possibly other related pinniped species.
    Journal of the American Veterinary Medical Association 10/2013; 243(8):1170-1178. · 1.72 Impact Factor
  • Biomedical and Environmental Sciences - BIOMED ENVIRON SCI. 01/2008; 21(2):91-97.